Overview

A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
A Phase III, Randomized, open-label, positive-drug parallel control, Study to Evaluate the Efficacy and Safety of TJ101 in Child subject with growth hormone deficieney.
Phase:
Phase 3
Details
Lead Sponsor:
I-Mab Biopharma Co. Ltd.